CLINICAL TRIALS PROFILE FOR IV PERSANTINE
✉ Email this page to a colleague
505(b)(2) Clinical Trials for Iv Persantine
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| New Formulation | NCT02273531 ↗ | Bioequivalence of a New Asasantin Formulation Extended Release (ER) Compared to the Commercially Available Asasantin Formulation (Aggrenox®; Extended Release) in Healthy Male and Female Volunteers | Completed | Boehringer Ingelheim | Phase 1 | 2004-01-01 | Study to establish the bioequivalence of a new formulation of Asasantin ER compared to the present commercially available Asasantin ER formulation (Aggrenox®) |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for Iv Persantine
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00003018 ↗ | S9700 Combination Chemotherapy in Treating Patients With Stage II or Stage III Pancreatic Cancer | Completed | National Cancer Institute (NCI) | Phase 2 | 1997-09-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Chemotherapy following surgery may be an effective treatment for pancreatic cancer. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with stage II or stage III pancreatic cancer that has not been surgically removed. |
| NCT00003018 ↗ | S9700 Combination Chemotherapy in Treating Patients With Stage II or Stage III Pancreatic Cancer | Completed | Southwest Oncology Group | Phase 2 | 1997-09-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Chemotherapy following surgery may be an effective treatment for pancreatic cancer. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with stage II or stage III pancreatic cancer that has not been surgically removed. |
| NCT00763009 ↗ | Persantine: Variation in Response Trial | Terminated | United States Department of Defense | Phase 4 | 2002-09-01 | The primary objective of this study is to understand why different people respond differently to the medication Persantine. The effects of Persantine will be evaluated by performing echocardiograms, blood tests and by measuring the flow of blood in the arteries of the heart in patients undergoing a clinically indicated percutaneous coronary intervention. |
| NCT00763009 ↗ | Persantine: Variation in Response Trial | Terminated | UConn Health | Phase 4 | 2002-09-01 | The primary objective of this study is to understand why different people respond differently to the medication Persantine. The effects of Persantine will be evaluated by performing echocardiograms, blood tests and by measuring the flow of blood in the arteries of the heart in patients undergoing a clinically indicated percutaneous coronary intervention. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Iv Persantine
Condition Name
Clinical Trial Locations for Iv Persantine
Trials by Country
Clinical Trial Progress for Iv Persantine
Clinical Trial Phase
Clinical Trial Sponsors for Iv Persantine
Sponsor Name
